Morningstar

Circle Pharma Unveils First Preclinical Data from Cyclin D1 Program at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for cancer, today presented preclinical data related to the company’s cyclin ...
Business Wire

Circle Pharma Presents Promising Preclinical Data on First-in-Class Oral Macrocycle Cyclin A/B RxL Inhibitor CID-078 at the San Antonio Breast Cancer Symposium 2024

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, a clinical-stage biopharmaceutical company dedicated to discovering and developing a new generation of macrocycle therapies, today ...
CU Boulder News & Events

MAPK and mTORC1 signaling converge to drive cyclin D1 protein production to enable cell cycle reentry in melanoma persister cells

[button url="http://chem.colorado.edu/" color="blue"]Department of Chemistry and Biochemistry[/button] [button url="www.colorado.edu" color="blue"]University of ...
BioWorld

CCNA2 deficiency impairs endometrial responsiveness to steroids

Cyclins regulate steroid receptor action in cyclin-dependent kinase (CDK)-dependent and independent manners. In addition to regulating the cell cycle, cyclin A2 (CCNA2) also mediates female sex ...
Morningstar

Circle Pharma Announces Nomination of CID-165, an Oral First-in-class Cyclin D1 RxL Inhibitor, as Development Candidate for its Second Oncology Program

Circle Pharma Announces Nomination of CID-165, an Oral First-in-class Cyclin D1 RxL Inhibitor, as Development Candidate for its Second Oncology Program Circle Pharma, Inc., a clinical-stage ...